EMVITAL + EMFACE Combination Therapy for Temporomandibular Joint (TMJ) Pain Relief
Evaluating the Safety and Efficacy of the BTL-043 and BTL-785F Devices in Alleviating Temporomandibular Joint (TMJ) Pain
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Florida
-
Leesburg, Florida, Stati Uniti, 34748
- The Dental Touch
-
Ocala, Florida, Stati Uniti, 34471
- Chandra Wellness Center
-
-
Kentucky
-
Covington, Kentucky, Stati Uniti, 41011
- Applegate Dentistry & MedSpa
-
-
Texas
-
Frisco, Texas, Stati Uniti, 75034
- Stonebriar Smile Design
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Age 22 years and older
- Voluntarily signed an informed consent form
- Subject is willing to comply with study instructions, to return to the clinic for the required visits
- Willingness to adhere to and continue current pain management plan
- Subjects willing and able to maintain their regular (pre-procedure) diet, exercise and therapy regimen without significant change during study participation
- Subject is willing and able to abstain from partaking in any new treatments other than this study procedure to treat TMJ pain
Women of child-bearing potential* are required to use birth control measures during the whole duration of the study
- Women of childbearing potential are defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.
Exclusion Criteria:
- Major systemic diseases - e.g., uncontrolled Diabetes mellitus, systemic lupus erythematosus
- Current pregnancy, nursing, or IVF procedure
- Photosensitivity, medications affecting sensitivity to light
- Tattoos or other higher pigmented regions in the treated area
- Corticosteroids or injections of the treated area within the last 3 months, long-term corticosteroids use
- Anticoagulant therapy, bleeding disorders
- Hemorrhage in the treated area
- Application over the thyroid or other endocrine glands
- Subjects currently undergoing, or who have received, radiation therapy or chemotherapy within the past 6 months prior to study treatment
- Known or suspected malignancy, history of cancer, any type of malignancy or pre-malignant moles
- Febrile conditions, serious illness, chronic infection
- Neurological disorders (such as multiple cerebrospinal sclerosis, epilepsy)
- Sensory or sensitivity disorders in the treatment area
- Active bacterial or viral infection, acute inflammation
- Impaired immune system
- Isotretinoin in the past 12 months
- Skin-related autoimmune diseases
- Poor healing and unhealed wounds in the treatment area
- Metal implants near the treatment area or neutral electrode
- Permanent implant near the treatment area
- Pacemaker or internal defibrillator, or any other active electrical implant, anywhere in the body
- Active collagen diseases
- Cardiovascular diseases (such as vascular diseases, peripheral arterial disease, thrombophlebitis and thrombosis)
- Any active condition in the treatment area, such as sores, psoriasis, eczema, rash and rosacea
- Any surgical procedure in the treatment area within the last three months or before complete healing
- Tuberculosis
- Hepatitis
- Poorly controlled endocrine disorders
- History of bleeding coagulopathies
- Acute neuralgia and neuropathy
- Kidney or liver failure
- Skin dermabrasion, skin resurfacing, or deep chemical peeling in the treatment area within 3 months prior to the treatment
- Electroanalgesia without exact diagnose of pain etiology
- Serious psychopathological disorders (such as schizophrenia)
- Inflammation of blood or lymphatic vessels
- Scarring in the treatment area
- Swollen, infected, or inflamed areas or damaged skin, skin eruptions, e.g., phlebitis, thrombophlebitis, varicose veins, etc.
- Hypersensitive carotid sinus
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Treatment with BTL-043 and BTL-785F device
|
All subjects will receive a consecutive treatment with the BTL-043 and BTL-785F devices during a single visit.
Subjects will be required to complete four (4) treatment visits and two (2) follow-up visits conducted at 1 month and 3 months after the last treatment.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from Baseline in the Visual Analogue Scale (VAS) Pain Score at 3 Months
Lasso di tempo: Baseline and 3 months
|
The Visual Analogue Scale (VAS) is a self-reported measure used to assess the intensity of TMJ-related pain experienced by the participants in the treatment area.
Participants rate their perceived pain level on a numerical scale ranging from 0 to 10.
On this scale, 0 is equivalent to "no pain" and 10 indicates the "worst possible pain".
The baseline score is compared to the score collected at the 3-month follow-up visit.
A negative change from baseline (a decrease in the VAS score) indicates a reduction in pain intensity and an improvement in the participant's condition over time.
|
Baseline and 3 months
|
|
Change from Baseline in the Temporomandibular Dysfunction (TMD) Disability Index Score at 3 Months
Lasso di tempo: Baseline and 3 months
|
The Temporomandibular Dysfunction (TMD) Disability Index is a self-reported questionnaire used to assess the impact of TMJ disorders on a participant's daily activities, such as talking, chewing, and sleeping.
The questionnaire consists of 10 categories, each containing 5 statements.
Each category is scored on a scale from 0 to 4, where 0 represents no limitation and 4 represents maximum restriction due to pain.
The overall score is calculated by summing the scores of all 10 items, resulting in a total possible score ranging from 0 to 40.
On this scale, a total score of 0 indicates no disability and 40 indicates extreme disability.
A negative change from baseline (a decrease in the total score) indicates a reduction in disability and an improvement in the participant's condition over time.
|
Baseline and 3 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from Baseline in Mandibular Range of Motion at 3 Months
Lasso di tempo: Baseline and 3 months
|
Mandibular range of motion is measured objectively in millimeters (mm) using a specialized scale.
Two measurements are taken: "comfort" (opening the mouth to a comfortable level without pain) and "active" (opening the mouth as wide as possible despite the presence of pain).
A positive change from baseline (an increase in the measured mm) indicates an improvement in jaw mobility.
|
Baseline and 3 months
|
|
Incidence of Treatment-related Adverse Events
Lasso di tempo: From baseline up to 3 months post-treatment
|
Overall safety is evaluated continuously by monitoring, assessing, and recording the occurrence and severity of any adverse events, side effects, or unanticipated problems throughout the course of the study
|
From baseline up to 3 months post-treatment
|
|
Change from Baseline in Lateral Range of Motion at 3 Months
Lasso di tempo: Baseline and 3 months
|
Lateral mandibular range of motion is measured objectively in millimeters (mm) using a specialized scale.
Two measurements are taken: left lateral excursion (moving the lower jaw as far as possible to the left) and right lateral excursion (moving the lower jaw as far as possible to the right).
A positive change from baseline (an increase in the measured mm) indicates an improvement in lateral jaw mobility.
|
Baseline and 3 months
|
|
Subject Satisfaction Assessed by the Subject Satisfaction & Quality of Life Questionnaire
Lasso di tempo: 3 months post treatment
|
Subject satisfaction with the treatment outcomes and its impact on quality of life is assessed using a 17-item self-reported questionnaire.
Each item is rated on a 5-point Likert scale, where 1 indicates "strongly disagree" and 5 indicates "strongly agree".
Higher scores represent greater treatment satisfaction and improvement in the subject's quality of life.
|
3 months post treatment
|
|
Therapy Comfort Assessed by the Therapy Comfort Questionnaire
Lasso di tempo: Immediately after the final treatment
|
Therapy comfort is assessed using a self-reported questionnaire.
Participants indicate their overall comfort on a 5-point Likert scale (where 1 is "strongly disagree" and 5 is "strongly agree" with the statement "I found the treatment comfortable").
Additionally, any pain experienced during treatment is rated on a Numerical Analogue Scale ranging from 0 ("no pain") to 10 ("worst possible pain").
Lower pain scores and higher agreement scores indicate greater therapy comfort.
|
Immediately after the final treatment
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Dolore
- Manifestazioni neurologiche
- Malattie muscoloscheletriche
- Malattie stomatognatiche
- Malattie muscolari
- Malattie articolari
- Malattie della mascella
- Malattie mandibolari
- Patologie craniomandibolari
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Disturbi dell'articolazione temporomandibolare
- Dolore al collo
- Dolore facciale
- Terapie
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- BTL-043_CTUS400
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .